Recent Research Funding

We receive funding from a variety of sources that recognize the value of our high-impact research.

Julian Ambrus, Jr., MD

  • Cytokines in Early Sjogren's Syyndrome. Julian Ambrus, Jr. (Co-Principal Investigator). Amgen. 1/1/2018-12/1/2020.
  • Investigation of anti-LTa in Sjögren’s syndrome in IL14aTG mice. Julian Ambrus, Jr. (Co-Principal Investigator). Genentech. 1/1/2018-12/1/2020.
  • Novel Role for the P2Y2 Receptor in the Autoimmune Disease Sjögren’s Syndrome. Julian Ambrus, Jr. (Co-Investigator). NIDCR. 1/1/2017-12/1/2022.

Supriya Mahajan, PhD, MPH

  • A novel phase and spectroscopic imaging technique to evaluate mitochondrial dynamics. Supriya Mahajan (Principal Investigator). National Institute of Drug Abuse (NIDA). $1,200,000. 2/1/2019-1/1/2022.
  • Mitochondrial dynamics in SARS-CoV-2 spike protein treated human CNS cells: Implications for COVID19 induced CNS hypoxia. Supriya Mahajan (Principal Investigator). SUNY Research Seed Grant Program. $5,000. 6/1/2020-10/1/2020.
  • Inhibition of Radiation-Induced Coronary Microvascular Disease. Supriya Mahajan (Co-Investigator). NIH. $1,750,000. 9/1/2020-8/1/2025.
  • Biomarkers for Type III Hereditary Angioedema. Supriya Mahajan (Co-Investigator). Takeda originally Shire. $275,000. 1/1/2018-12/1/2023.
  • Oral Microbiome in HIV+ patients with Thrush. Supriya Mahajan (Principal Investigator). Buffalo Blue Sky Award UB VPR Office. $35,000. 1/1/2020-3/1/2022.

Jessica Reynolds, PhD

  • Pharmacokinetics and Immunodynamics of Immune stimulating chemotherapeutic nanoparticles for TB. Jessica Reynolds (Principal Investigator). NIAID. $2,197,275. 8/1/2018-7/1/2023.